Delivery Order SPE2DB22D2005-SPE2DB25FJMV5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,325.03 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services under...
- The Defense Logistics Agency (DLA) awarded a $16,338.29 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors under a firm fixed-price contract type. This award, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a non-competitive delivery against an existing indefinite delivery contract. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at approximately $42,601.58 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion on June 20, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $27,537.91 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on April 23, 2025, with completion scheduled for April 24, 2025. This non-compete delivery order represents a pharmaceutical supply transaction under the company's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $34,200.83 under a firm fixed price contract type. The order was competitively awarded without set-aside designations and is scheduled for completion by August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a $11,697.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a pediatric or maintenance supply delivery under DLA's medical procurement operations. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $4,505.02 delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance scheduled to conclude on September 30, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJMV5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,928.20 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on May 27, 2025, with an ultimate completion date of May 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's demonstrated capability to fulfill federal medical supply requirements through competitive procurement, combined with its extensive portfolio of specialty medications and brand-name pharmaceuticals, positions it as a critical vendor for the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.9k | 5/27/25 |